• Are there any reliable techniques to assess antipsychotic medication adherence?

• Management of tardive movement disorders

• What are some strategies for reducing the adverse effects of antipsychotic medications for people with SMI?

• What did we learn from the STAR*D study?

• What did we learn from CATIE study?

• What is the Research Domain Criteria (RDoC) framework and what are its implications for clinical care?

• What are the pros and cons of taking a long acting injectable antipsychotic medication?

• What side effects might be expected after starting an antidepressant medication for the first time?

• Does smoking cigarettes interfere with how well medication for schizophrenia works?

• What is the difference between the older and newer antipsychotic medications?

• What is neuroleptic malignant syndrome?

• What is the best antidepressant?

• How do you treat akathisia from treatment with long-acting injectable antipsychotics (LAIs)?

• What is the best antidepressant to use in children?

• How long should a person take medication for their mental illness before changing the dosage or the type of medication being used?

• Can a primary care provider or family practitioner prescribe psychotropic medications?

• Is a person ever able to stop taking medications to treat their serious mental illness?

• Why are many of the medications used to treat schizophrenia today the same ones that were used 15-30 years ago?

• Practice Guidelines for the Psychiatric Evaluation of Adults, Third Edition

• Why is it common for people with serious mental illness to need more than one medication?

• Can the medications used to treat serious mental illness (antipsychotics and antidepressants) be addicting?

• How often should a full medical workup be done on a person with serious mental illness who is being treated with medications?

• Is weight gain or obesity a side effect of antipsychotic medications, and what can be done?

• What about ketamine for depression or suicidal ideation?

• Can antipsychotic medications cause neutropenia or agranulocytosis as a side effect?

• What metabolic monitoring is appropriate when patients are taking antipsychotic medication? Are there any labs or vital signs to monitor?

• Comparative Effectiveness Review Number 215: Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults

• What is the evidence regarding combining multiple antipsychotic medications?

• What should I consider with an older patient who develops new onset tardive dyskinesia while taking antipsychotic medication?

• What is known about psychiatric disorders in people with a mitochondrial myopathy?

• What treatments are available for postpartum depression, or depression after childbirth?

• What are the long-term effects of common antidepressant medications, such as SSRIs or SNRIs? Do they cause permanent changes?

• First and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update

• MedTEAM (Medication Treatment, Evaluation, and Management) Evidence-Based Practices (EBP) Kit

• What should I do if a patient misses a scheduled dose of, or experiences a gap in their long-acting injectable (LAI) treatment?

• How do I establish tolerability before starting a long-acting injectable antipsychotic medication (LAI), and how do I ensure the patient will not have side effects?

• What about asymptomatic increases in liver function tests or transaminases while taking psychotropic medication?

• What if hepatitis or liver cirrhosis develops in patients taking anti-psychotic medication?

• Medication Management of Bipolar Disorder During the Reproductive Years

• Maintenance Dose Conversion Between Oral Risperidone and Paliperidone Palmitate 1 Month: Practical Guidance Based on Pharmacokinetic Simulations

• Clozapine Center of Excellence

• Are there concerns regarding urinary retention and antidepressant medications?

• Discontinuing Antipsychotic Medication after an Episode of Psychosis

• Guide to Long-Acting Medications for Providers and Organizations – Reserved for Treatment-Resistant cases?

• Long-acting injection antipsychotic medications in the management of schizophrenia (excerpt from APA Clinical Practice Guideline)

• Aspiration in injections: Should we continue or abandon the practice?

• What is post-injection delirium sedation syndrome (PDSS) that is associated with the olanzapine long-acting injectable (Zyprexa Relprevv)?

• Long-Acting Injectables: Pharmacological Information – LAI Table of Considerations

• What about prescribing anticholinergic medications such as benztropine to patients taking antipsychotic medications?

• When prescribing, what should I consider regarding doses of antipsychotic medications, oral or long-acting injectable medications?

• What is known about tinnitus, antidepressant medications, depression, and anxiety?

• What should clinicians know about risperidone or Risperdal Consta (“Consta”) (risperidone microspheres LAI)?

• What should clinicians know about Abilify Maintena (aripiprazole monohydrate LAI)?

• What should clinicians know about Perseris (risperidone subcutaneous LAI)?

• Recorded Bipolar Psychopharmacology Consultation Line Webinar

• What should clinicians know about Aristada Initio (aripiprazole lauroxil LAI)?

• What should clinicians know about Aristada (aripiprazole lauroxil LAI)?

• Long-Acting Injectable Center of Excellence

• What should clinicians know about haloperidol decanoate (“Haldol Dec”)?

• What should clinicians know about fluphenazine decanoate (“Prolixin Dec”)?

• What should clinicians know about Invega Trinza (paliperidone palmitate 12-week LAI)?

• Are there antipsychotic medication handouts for patients?

• Are there any concerns with regard to prescribing or using concomitant medications or substances during treatment with ketamine or transcranial magnetic stimulation (TMS)?

• What long-acting injectable (LAI) antipsychotic medications are available in the U.S.?

• What should a provider consider when administering long-acting injectable (LAI) antipsychotics?

• Are paliperidone (Invega) and risperidone (Risperdal) similar or different?

• Are there patient handouts regarding long-acting injectable (LAI) antipsychotic medications?

• What should I consider and how do I change or switch a patient from a different long acting injectable medication (LAI) to Abilify Maintena?

• What should clinicians know about Invega Sustenna (paliperidone palmitate LAI)?

• What mistakes should providers be aware of when prescribing and administering long-acting injectables (LAIs)?

• What should providers consider when talking to patients and their families about starting a long-acting injectable (LAI) antipsychotic?

• What is known about catatonia in serious mental illness, such as bipolar disorder or schizophrenia?

• What are approaches for treating or managing anxiety in patients with schizophrenia who are taking clozapine?

• What are important considerations for the use of long-acting injectable (LAI) antipsychotic medications in first-episode psychosis patients?

• What is known about long acting injectable (LAI) antipsychotic medications in the treatment of schizophrenia or bipolar disorder?

• What is known about overlapping or cross-titration of psychiatric medications?

• What is known about the causes of restless legs or akathisia?

• What is known about lumateperone tosylate (Caplyta) for psychosis or schizophrenia?

• What should clinicians who work with American Indian/Alaska Native people consider when prescribing long-acting injectable (LAI) antipsychotics?

• What is known about therapeutic drug monitoring (TDM) for antipsychotic medications?

• Is there anything that can be done if a patient experiences sedation as a side effect after a long-acting injectable (LAI) deltoid injection?

• How do I transition a patient from risperidone oral to paliperidone palmitate (Invega Sustenna) long-acting injectable (LAI)?

• What are clinical situations where the use of an oral antipsychotic together with a long-acting injectable (LAI) antipsychotics may make sense?

• What are clinical indications for the use of long-acting injectable (LAI) antipsychotics?

• Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness

• What is shared decision making and how does it apply to using long-acting injectables (LAIs)?

• What can be done if a LAI medication becomes less effective part way through the inter-injection interval?

• How can I better understand the challenges of using medication as part of the treatment of mental illness?

• What is meant by the phrase “optimal use of medication” as it relates to treatment of mental illness?

• What are clinical considerations for giving LAIs during the COVID-19 public health emergency?

• Can risperidone, paliperidone (Invega) or first generation antipsychotic medications cause elevated or high prolactin levels, and related side effects such as sexual dysfunction, gynecomastia or galactorrhea?

• What should I consider and how do I change or switch a patient from a different long acting injectable (LAI) antipsychotic medication to Aristada?

• Are antipsychotic drug dose equivalents derived using the Defined Daily Doses (DDD) method useful in clinical practice?

• Clinical use of lithium salts: guide for users and prescribers

• Antidepressants in bipolar depression: an enduring controversy

• Evaluating patient satisfaction with pharmacist-administered long-acting injectable antipsychotics in the community pharmacy

• What should I consider and how do I change or switch a patient from a different long-acting injectable medication (LAI) to Invega Sustenna (paliperidone palmitate)?

• What should clinicians know about Zyprexa Relprevv (olanzapine for extended release injectable suspension)?

• How can I manage extrapyramidal side effects from long-acting injectable antipsychotics (LAIs)?

• How do I treat an acute dystonic reaction (ADR)?

• WEBINAR: COVID-19 – How to Support Ourselves and Others Through Times of Fear and Isolation

• When should you offer a long-acting injectable (LAI) for first-episode patients?

• What are dose conversions from oral to injectable for the long-acting injectable (LAI) antipsychotic medications available in the U.S.?

• Long-acting injectable antipsychotics (LAIs) use for older adults

• How are prolactin levels impacted by long-acting injectable (LAI) antipsychotic medications?

• What is recommended for handling waste associated with administration of long-acting injectable antipsychotics (LAIs)?

• How do I switch a patient treated with LAI to Risperdal Consta (risperidone microspheres)?

• What drug-drug interactions should you be vigilant for when someone is prescribed carbamazepine?

• Is there a role for therapeutic drug monitoring when someone is prescribed carbamazepine?

• Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness

• Should clinicians massage the injection site when giving long-acting injectable antipsychotic (LAI) injections?

• Clozapine & LAI Virtual Forum – August 2020 (Video) – Clozapine hematologic monitoring and COVID-19

• Clozapine & LAI Virtual Forum – September 2020 (Video) – Antipsychotic conversion to LAIs

• Clozapine & LAI Virtual Forum – October 2020 (Video) – Understanding and mitigating clozapine-induced myocarditis

• What do APA’s Schizophrenia Treatment Guidelines say about long-acting injectable antipsychotics?

• Clozapine & LAI Virtual Forum – November 2020 (Video) – Early psychosis and LAIs

• In what states may pharmacists legally administer long-acting injectable antipsychotic medications?

• Clozapine & LAI Virtual Forum – December 2020 (Video) – Pharmacologic and psychosocial strategies for a partial Clozapine response

• Clozapine & LAI Virtual Forum – January 2021 (Video) – Strategies for managing breakthrough symptoms for patients on LAIs

• What are some factors that lead to medication non-adherence for people with serious mental illness?

• Clozapine & LAI Virtual Forum – February 2021 (Video) – Clozapine titrations: new starts and re-titrating after treatment interruption

• Antipsychotic Receptor Binding Properties

• Are antidepressants safe for individuals who have bipolar disorder?

• Clozapine & LAI Virtual Forum – March 2021 (Video) – LAIs during COVID-19

• Clozapine & LAI Virtual Forum – May 2021 (Video) – Interpreting plasma levels for patients on LAIs

• Clozapine & LAI Virtual Forum – July 2021 (Video) – Is there a role for First-Generation Antipsychotic (FGA) LAIs?

• Clozapine & LAI Virtual Forum – August 2021 (Video) – Case Study: Clozapine and Cognition

• Clozapine & LAI Virtual Forum – September 2021 (Video) – Talking to patients and family members about LAIs

• Guidance for Missed Maintenance Doses for Long Acting Injectable Antipsychotics

• What should clinicians know about Invega Hafyera (paliperidone palmitate 6-month LAI)?

• Long Acting Injectable (LAI) Antipsychotic Use During Pregnancy

• Clozapine & LAI Virtual Forum – November 2021 (Video) – The role of LAIs in crisis prevention and response

• Talking to Individuals and Families About Long-Acting Injectables

• Clozapine & LAI Virtual Forum – February 2022 (Video) – LAI antipsychotics and oral augmentation and overlap

• What is tardive dyskinesia (TD)?

• Clozapine & LAI Virtual Forum – May 2022 (Video) – Long-Acting Injectable (LAI) Antipsychotics and Antipsychotic Polypharmacy (APP)

• What is deprescribing?

• Antipsychotics and heat-related illnesses

• Clozapine & LAI Virtual Forum – August 2022 (Video) – LAI Discontinuation

• Video: Intramuscular (IM) Injection of Long-acting Injectables into Deltoid Site

• Video: Intramuscular (IM) Injection of Long-acting Injectables into Ventral Gluteal (or Ventrogluteal) Site

• Video: Intramuscular (IM) Injection of Long-acting Injectables into Dorsal Gluteal (or Dorsogluteal) Site

• Video: Subcutaneous (SC) Injection of Long-acting Injectables into Abdominal Site

• Clozapine & LAI Virtual Forum – October 2022 (Video) – LAIs and troubleshooting insurance coverage

• Clozapine & LAI Virtual Forum – November 2022 (Video) – Management of clozapine-induced constipation

• Clozapine & LAI Virtual Forum – December 2022 (Video) – Pharmacist administration of LAIs

• Video: Subcutaneous (SC) Injection of Long-acting Injectables into Lateral Aspect of Upper Arm

• Clozapine & LAI Virtual Forum – February 2023 (Video) – Comprehensive Screening for Antipsychotic-Induced Movement Disorders Via Telehealth

• Clozapine & LAI Virtual Forum – April 2023 (Video) – Physical Health / Cardiometabolic Monitoring for Patients on LAIs

• What should clinicians know about Uzedy (risperidone subcutaneous LAI)?

• What should clinicians know about Abilify Asimtufii (aripiprazole LAI)?

• Clozapine & LAI Virtual Forum – June 2023 (Video) – Update on the Long-Acting Injectable Antipsychotic Medications

• Clozapine & LAI Virtual Forum – September 2023 (Video) – Making Sense of the Long-Acting Injectable (LAI) Antipsychotic Medication Research

• Clozapine & LAI Virtual Forum – October 2023 (Video) -Debrief on New Long-acting Injectable Antipsychotic Medications (LAIs)

• Clozapine & LAI Virtual Forum – November 2023 (Video) – Demystifying Lithium’s Renal Effects

• Clozapine & LAI Virtual Forum – December 2023 (Video) – Comparing Risperidone and Paliperidone LAI Products

• Clozapine & LAI Virtual Forum – February 2024 (Video) – Comparing Aripiprazole LAI Products

• What should clinicians know about Brixadi (Subutex)?

• What should clinicians know about Vivitrol (Naltrexone)?

• What should clinicians know about Sublocade (Suboxone)?

• Clozapine & LAI Virtual Forum – April 2024 (Video) – LAIs and VMAT2 Inhibitors

• How do I prescribe lithium?

• Maximizing Treatment Outcomes with Lithium: A Video Series for Healthcare Professionals

• Clozapine & LAI Virtual Forum – June 2024 (Video) – Therapeutic Drug Monitoring (TDM) for Antipsychotic Medications